Panacea Biotec has announced the inclusion of its EmulsiPan adjuvant in the CEPI Adjuvant Library, marking its entry into the commercialization of adjuvants. EmulsiPan enhances vaccine efficacy and has a potential market value of over $4.8 billion by 2028.